How to Verify Peptide Purity Independently

Independent purity verification is not optional bookkeeping, it is the analytical foundation on which every downstream experimental conclusion rests. A research peptide reported by a supplier as ≥98% pure by area-percent RP-HPLC can simultaneously contain sequence-deletion impurities, oxidised side chains, or high-molecular-weight aggregates that no single UV chromatogram will reveal. 1 The gap between a supplier's certificate of analysis and what actually arrives at your bench is not theoretical: analyses of commercially sourced research peptides have detected impurities exceeding 5% that were absent from accompanying CoAs, with direct consequences for receptor binding data and cell-based assay outputs. 2

This protocol translates current best practice into a reproducible, step-by-step workflow that any moderately equipped biochemistry or pharmacology laboratory can execute. The core strategy is orthogonal verification: two or more physicochemically independent methods applied to the same sample, so that impurities invisible to one detector are exposed by another. 3 The workflow presented here centres on reversed-phase HPLC (RP-HPLC) for area-percent purity, electrospray ionisation mass spectrometry (ESI-MS) for molecular weight confirmation and impurity identification, and amino acid analysis (AAA) for absolute quantitation, supplemented by targeted assays for disulfide integrity and aggregate detection where the peptide sequence warrants them.

Before executing this protocol, read our companion guides on how to read a certificate of analysis and how to choose a peptide supplier, which provide the supplier-side context that makes independent verification interpretable.

Quick Summary

The four-stage verification hierarchy recommended in this protocol, (1) RP-HPLC area-percent purity, (2) ESI-MS molecular weight confirmation, (3) AAA absolute quantitation, and (4) orthogonal structural assays, mirrors the tiered approach described in regulatory guidance for therapeutic peptide characterisation. 4 Laboratories with access only to HPLC should at minimum outsource ESI-MS to a core facility; the mass accuracy data are non-negotiable for unambiguous identification. Conversely, AAA can be deferred for exploratory studies but becomes mandatory whenever stoichiometric dosing is critical to the experimental design. 5

Why This Protocol Matters

The reproducibility cost of unverified purity

The reproducibility crisis in biomedical research has multiple roots, but impurity-contaminated reagents represent a consistently underappreciated contributor. A systematic survey by Kaspar and Reichert identified peptide impurity as a leading source of inter-laboratory variability in receptor pharmacology assays, particularly for GPCRs where partial agonist impurities at concentrations as low as 2-3% can shift apparent EC₅₀ values by up to fivefold. 2 The mechanism is straightforward: deletion sequences, peptides missing one or more residues from the intended sequence, frequently retain partial receptor affinity while lacking full efficacy. When such impurities accumulate, the observed dose-response curve reflects a mixture of full agonist and partial agonist activities that is indistinguishable from genuine low-efficacy behaviour at the target receptor without independent purity data. 2

The consequences extend beyond data quality. Undetected aggregates in peptide samples can alter biodistribution in animal models, reducing renal clearance and prolonging tissue exposure in ways that mimic pharmacological effects unrelated to the target peptide. 6 Immunogenic impurities, even at sub-0.5% concentrations, can confound immunological endpoints in rodent studies, rendering whole experimental series uninterpretable. 2 These are not edge cases; they are documented failure modes with published examples across therapeutic peptide classes including GLP-1 analogues, opioid receptor ligands, and antimicrobial peptides. 2

What a supplier's CoA cannot tell you

A certificate of analysis from a peptide vendor communicates the results of testing performed on the synthesis batch, often weeks or months before the vial reaches your lab. That interval matters because peptides degrade during shipping and storage, and certain degradation pathways, asparagine deamidation, methionine oxidation, cysteine disulfide scrambling, can produce substantial impurity burdens within days under suboptimal temperature or humidity conditions. 7 A CoA reporting 98.5% purity at the time of batch release provides no information about the purity of the material you are about to pipette.

Supplier CoAs also vary enormously in methodological rigour. Area-percent purity calculated from a single RP-HPLC run at a single UV wavelength (typically 214 nm) is the most common reporting format, yet it systematically overestimates the purity of samples containing UV-transparent impurities such as TFA salts, residual protecting groups, or peptide aggregates that scatter rather than absorb UV light. 3 Our guide to reading CoAs walks through how to interpret supplier documents; this protocol explains how to generate your own data that either corroborates or contradicts those documents.

Regulatory and scientific precedent

FDA guidance on drug substance impurities in peptide ANDAs explicitly requires characterisation of impurities present at ≥0.1% and safety evaluation of those present at ≥0.5%, using a minimum of two orthogonal analytical methods. 2 USP General Chapter ⟨1086⟩ establishes a framework for impurity control in synthetic peptides that applies equally to research-grade material when experimental conclusions depend on purity. 4 While research peptides are not subject to regulatory submission, the scientific logic of these frameworks, that a single method creates blind spots, applies universally.

Materials and Equipment

The table below catalogues every item required for the full orthogonal panel. Laboratories performing only RP-HPLC + ESI-MS (the minimum acceptable workflow) can focus on rows marked "Core"; items marked "Extended" apply to AAA and structural assays.

Step-by-Step Protocol

The protocol below is written as a numbered sequence within each stage. Each step includes the scientific rationale so that analysts can make informed judgements when conditions deviate from ideal.

Stage 1: Sample preparation

Step 1, Weigh and record. Tare a low-protein-binding 1.5 mL microtube on the calibrated analytical balance. Transfer approximately 1-2 mg of lyophilised peptide directly from the vial using a clean spatula. Record the exact mass to 0.01 mg. Perform this step with the vial at ambient temperature, equilibrated for 15 minutes after removal from cold storage, to prevent moisture condensation on the cold powder that would alter the effective mass. 9

Step 2, Prepare stock solution. Dissolve the peptide in an appropriate diluent. For most hydrophilic peptides, 0.1% TFA in water (mobile phase A) is suitable at 1-2 mg/mL. For hydrophobic peptides (GRAVY score > 0), pre-dissolve in a minimum volume of DMSO (≤10% of final volume) then dilute with 0.1% TFA/water. Vortex gently for 30 seconds; do not sonicate cysteine-containing peptides, as ultrasound accelerates disulfide scrambling. 7 Blanket the headspace with nitrogen or argon before capping.

Step 3, Clarify by centrifugation. Centrifuge the stock solution at 10,000 × g for 5 minutes at 4 °C. Transfer the supernatant to a fresh labelled tube without disturbing the pellet. If a visible pellet forms, this is significant: record its presence, weigh the dry mass after lyophilisation if possible, and note that your dissolved fraction may represent substantially less than the nominal weighed mass. Aggregation at this stage indicates either poor solubility, pre-existing aggregates, or contamination with insoluble excipients.

Step 4, Prepare analytical working solution. Dilute the clarified stock to 0.5-1.0 mg/mL for RP-HPLC injection. Lower concentrations (0.1-0.2 mg/mL) may be required if peak overloading is observed. For ESI-MS, dilute further to 10-100 µg/mL in 50% acetonitrile / 0.1% formic acid (note: TFA suppresses ionisation; switch to formic acid for direct infusion MS). 10

Stage 2: RP-HPLC analysis

Step 5, Equilibrate the system. Flush the HPLC system with five column volumes of mobile phase A (0.1% TFA in water) followed by ten column volumes of the starting gradient composition. Run a blank injection (diluent only) and confirm the baseline absorbance is stable at 214 nm with noise below 0.5 mAU. A drifting or noisy baseline at this stage is the most common source of phantom peaks in final chromatograms and must be resolved before sample injection. 8

Step 6, Set gradient conditions. A generic starting point for analytical purity assessment is:

• Mobile phase A: 0.1% TFA in water
• Mobile phase B: 0.1% TFA in acetonitrile
• Gradient: 5% B to 65% B over 30 minutes (linear, 2%/min)
• Flow rate: 1.0 mL/min
• Column temperature: 25 °C (controlled)
• Detection: 214 nm primary, 280 nm secondary (if Trp or Tyr present)
• Injection volume: 10-20 µL

This gradient is intentionally broad to ensure all potential impurities are eluted and detected. Subsequent methods may use narrower gradients centred around the main peak for improved resolution of closely eluting species. 8

Step 7, Inject in triplicate. Run a minimum of three analytical injections from the same stock to assess system repeatability. The relative standard deviation (RSD) of main-peak area should be ≤1.0% for a validated system; RSDs above 2.0% indicate injection variability, inadequate mixing of mobile phases, or column inconsistency that must be resolved before results are reportable. 9

Step 8, Calculate area-percent purity. Integrate all peaks with area >0.05% of total area. Area-percent purity is calculated as:

Purity (%) = [Main peak area / Sum of all peak areas] × 100

Exclude solvent peaks and known mobile-phase impurity peaks (identified by blank injection). Report the mean ± SD from the triplicate run. A purity value ≥95% area-percent is the typical minimum threshold for research-grade material, though many experimental designs demand ≥98%. 3

Step 9, Collect fractions (optional). For impurity identification, fraction-collect peaks of interest (≥0.5% area) for subsequent MS analysis. Even without fraction collection, the retention time of each impurity peak provides a first hypothesis about its identity: earlier-eluting impurities are more hydrophilic (deamidated, truncated, or desalted species), while later-eluting peaks suggest more hydrophobic variants (protected, oxidised, or extended sequences). 8

Stage 3: ESI-MS molecular weight confirmation

Step 10, Prepare MS sample. Dilute the peptide stock to 10-50 µg/mL in 50% acetonitrile / 0.1% formic acid. Avoid TFA in MS samples; it suppresses electrospray ionisation and causes adduct formation that complicates spectral interpretation. 10

Step 11, Acquire spectrum. For direct infusion ESI-MS, inject at 5-10 µL/min and acquire for 1-2 minutes. For LC-MS, use the same RP-HPLC gradient with ammonium formate (10 mM, pH 3.0) replacing TFA as the ion-pairing agent, note that this changes retention times, so the LC-MS chromatogram is not directly comparable to the TFA-based analytical HPLC run. 10

Step 12, Calculate experimental molecular weight. ESI-MS produces multiply charged ions. Deconvolute the spectrum using the charge-state envelope:

MW (experimental) = (m/z × z) − (z × 1.00728)

where z is the charge state and 1.00728 is the proton mass in Da. Compare to the theoretical monoisotopic or average molecular weight (use average MW for peptides >2 kDa where isotope peaks are unresolved). Agreement within ±0.5 Da (low-resolution instruments) or ±0.01 Da (high-resolution instruments) confirms molecular identity. 10

Step 13, Interpret impurity peaks. Common mass offsets and their interpretations:

For each mass-shifted species detected, assess whether the impurity is synthesis-related (likely present in the original batch) or degradation-related (may indicate inappropriate storage or handling). 10

Stage 4: Amino acid analysis (quantitative)

Step 14, Prepare hydrolysate. Transfer a known volume of clarified stock (containing approximately 50-200 nmol of peptide based on nominal concentration) to a sealed hydrolysis ampule. Add 200 µL of 6 N HCl, purge with nitrogen, seal, and hydrolyse at 110 °C for 24 hours. This cleaves all peptide bonds to free amino acids, destroys tryptophan and converts asparagine to aspartate, glutamine to glutamate, and cysteine (as its oxidised form) to cysteic acid. 5

Step 15, Derivatise and analyse. After hydrolysis, evaporate HCl under vacuum. Reconstitute in citrate buffer (pH 2.2 for ion-exchange AAA) or perform pre-column derivatisation with phenylisothiocyanate (PITC), OPA, or AccQ·Tag reagent depending on the available instrument. Inject onto the amino acid analyser and compare peak ratios to the theoretical composition. 5

Step 16, Calculate absolute concentration. Using the molar ratio of a unique residue (e.g., a single leucine or phenylalanine in the sequence), back-calculate the molar concentration of the original stock. This value is used to determine the true concentration independently of any assumed extinction coefficient or mass, and is the gold-standard approach for stoichiometric dosing in pharmacological experiments. 5

Stage 5: Supplementary structural assays

Step 17, Free thiol quantitation (cysteine peptides). Prepare Ellman's reagent (0.1 mM DTNB in 0.1 M sodium phosphate, pH 8.0). Mix peptide sample (1-5 nmol) with Ellman's reagent in a 1:1 ratio. Incubate 15 minutes at room temperature. Measure absorbance at 412 nm. Free thiol concentration = Abs₄₁₂ / (ε × path length), where ε = 14,150 M⁻¹cm⁻¹ for the released TNB anion. Compare measured free thiols to the expected number of cysteine residues; a deficit indicates partial or complete disulfide bond formation or oxidation. 7

Step 18, Aggregate detection by DLS. Prepare peptide at 0.5-1.0 mg/mL in the intended assay buffer. Filter through a 0.22 µm membrane to remove dust, then transfer to a DLS cuvette. Acquire three consecutive measurements and average. A monodisperse peak with hydrodynamic diameter consistent with the monomeric peptide (typically 0.5-3 nm for peptides <5 kDa) and polydispersity index (PDI) <0.1 indicates a non-aggregated preparation. PDI >0.3 or secondary peaks at >10 nm indicate aggregation that must be characterised before experimental use. 6

Common Mistakes to Avoid

Mistake 1: Reporting area-percent as mass-percent

The most widespread error in peptide purity assessment is treating RP-HPLC area-percent values as equivalent to mass-percent or molar-percent purity. Area-percent purity is a UV-response-weighted ratio that overestimates the purity of samples containing impurities with higher molar absorptivity at 214 nm (e.g., aromatic-residue-rich impurities) and underestimates purity when such residues are present predominantly in the main peak. 8 For research applications, area-percent is a valid screening tool, but absolute purity requires reference-standard-normalised HPLC or AAA. Always label results clearly as "area-percent purity by RP-HPLC at 214 nm" rather than simply "purity."

Mistake 2: Single-wavelength UV detection

Detecting at 214 nm maximises sensitivity for the peptide bond but is blind to UV-transparent impurities including TFA salts, succinimide intermediates, and certain protecting-group fragments that can exceed 5% of total sample mass. 3 Always acquire a second chromatogram at 280 nm if the peptide contains Trp or Tyr, and consider a photodiode array (PDA) detector to collect the full spectrum across the elution window. A peak with an anomalous 214/280 nm absorbance ratio compared to the main peak is a strong indicator of a structurally distinct impurity, not a variant of the target peptide.

Mistake 3: Incomplete system suitability before sample injection

Injecting samples before establishing that the system is performing to specification is the second most common source of erroneous purity data. System suitability criteria that must be confirmed before each analytical sequence include: blank baseline stability (<0.5 mAU noise at 214 nm), peak asymmetry factor for a reference standard (0.9-1.2 for acceptable peak shape), and theoretical plate count ≥5,000 plates for the reference standard peak. 9 Skipping system suitability to save time routinely costs more time when suspect data must be invalidated and samples re-analysed.

Mistake 4: TFA carryover into ESI-MS samples

TFA is an excellent RP-HPLC mobile phase additive but profoundly suppresses ESI ionisation, with as little as 0.01% TFA reducing ion signal by up to 70% for some peptides. 10 Never inject HPLC fractions collected in 0.1% TFA directly into an ESI-MS instrument without first either lyophilising and reconstituting in formic acid/acetonitrile, or performing an online desalting step. This error systematically underestimates impurity signals in LC-MS, causing false confidence in peptide purity.

Mistake 5: Neglecting sample oxidation during preparation

Atmospheric oxygen dissolved in aqueous solvents oxidises methionine and cysteine residues rapidly during sample preparation, particularly at alkaline pH. A sample prepared in unblanked water at pH 7 can show 3-5% oxidation artefact within 30 minutes, generating a false +16 Da impurity peak in the MS spectrum and an additional early-eluting peak in the RP-HPLC chromatogram that did not exist in the original lyophilate. 7 Always degas solvents under vacuum or by nitrogen sparging, blanket sample headspaces with inert gas, and keep sample preparation time short. If oxidation artefacts are suspected, compare fresh samples with identically prepared samples spiked with 0.01% ascorbic acid.

Mistake 6: Ignoring the pellet from centrifugation

When centrifuging a dissolved peptide sample (Step 3 above), any visible pellet represents material that was never in solution and will not appear in the chromatogram. If 10% of nominal mass is insoluble, a sample nominally prepared at 1 mg/mL is actually at 0.9 mg/mL, and the HPLC purity value applies only to the soluble fraction. The aggregate pellet may represent the most biologically active form of the peptide (as in the case of amyloidogenic sequences) or may be entirely inert contaminant, but its presence must be documented. 6

Advanced Considerations

Chiral purity and diastereomeric impurities

Racemisation during solid-phase peptide synthesis, particularly at amino acids alpha-positioned to activated carboxyl groups during coupling, can introduce D-amino acid residues at any position in the sequence. 11 Diastereomeric peptides containing one or more D-residues share identical molecular weight with the target L-peptide and often have nearly identical hydrophobicity, making them nearly undetectable by standard RP-HPLC or ESI-MS. Chiral HPLC columns (e.g., Chirobiotic T or CROWNPAK CR) can resolve diastereomers after acid hydrolysis of the peptide to free amino acids, but this approach is destructive and requires authentic D-amino acid standards. 11

An alternative non-destructive approach is chiral derivatisation before RP-HPLC: react free amino acids (post-hydrolysis) with Marfey's reagent (1-fluoro-2-4-dinitrophenyl-5-L-alanine amide, FDAA), which converts enantiomeric amino acids to diastereomers separable on standard C18 columns. 11 The limitation is that this method detects only D-amino acid content per residue type, not at which specific position in the sequence the D-residue occurs. For positional information, enzymatic degradation laddering with stereospecific proteases combined with MS sequencing is required, but this is a highly specialised technique beyond routine laboratory capability.

The practical implication for most research applications is that high-coupling-efficiency SPPS chemistry (HATU/DIPEA with short coupling times) minimises racemisation but does not eliminate it entirely. For peptides where stereochemistry is pharmacologically critical, such as those binding stereospecific enzyme active sites, commissioning a chiral purity assay from a specialised contract laboratory is appropriate. 11

Disulfide bond topology verification

Peptides containing two or more cysteine residues can form multiple disulfide bond regioisomers with identical molecular weight but distinct biological activity. Oxytocin (one disulfide), α-conotoxins (two disulfides), and defensins (three disulfides) are well-characterised examples where incorrect disulfide connectivity abolishes or inverts biological function. 7 The Ellman's assay described in Step 17 confirms only that disulfide bonds are present (or absent), not their connectivity.

Disulfide mapping requires partial reduction with tris(2-carboxyethyl)phosphine (TCEP) at controlled stoichiometry, followed by alkylation of the released thiols with iodoacetamide and MS/MS sequencing of the resulting fragments. 7 This is technically demanding and best outsourced to a core proteomics facility. For routine quality control of disulfide-bonded peptides, a combination of native RP-HPLC (comparing retention time to reduced/alkylated control) and non-denaturing MS at physiological pH provides sufficient evidence of correct folding for most research applications without full disulfide mapping.

Handling hydrophobic peptides

Peptides with a grand average of hydrophobicity (GRAVY) score above +0.5 present specific challenges for both dissolution and HPLC analysis. They are prone to adsorption to polypropylene tube walls, loss on HPLC column frits, and self-aggregation at concentrations above their critical aggregation concentration (CAC), which can be as low as 10-50 µg/mL for strongly hydrophobic sequences. 6 For these peptides:

• Dissolve in neat DMSO first (≤10% final DMSO content) before aqueous dilution
• Use silanised glassware rather than plastic tubes for sample storage
• Reduce sample concentration to 0.1-0.2 mg/mL and verify linearity of response at this concentration
• Confirm the HPLC mobile phase does not precipitate the peptide by running a slow gradient (0.5%/min)

For extremely hydrophobic peptides (GRAVY >1.0), reversed-phase analysis in formic acid / isopropanol / water mobile phases may provide better solubility than acetonitrile-based systems, though method validation for this condition requires additional work. 8

Phosphopeptide and glycopeptide analysis

Post-translationally modified synthetic peptides carry additional analytical challenges. Phosphate groups are labile under acidic MS conditions, producing neutral-loss peaks (−80 Da per phosphate) that can be mistaken for sequence-based impurities. 10 Analyse phosphopeptides in negative ion mode ESI-MS where phosphate anions stabilise. Glycopeptides produce broad, heterogeneous HPLC peaks due to glycan micro-heterogeneity; area-percent purity is essentially uninformative for glycopeptides unless a specific glycoform is targeted, and MS analysis of the glycan composition is mandatory. 10

Troubleshooting

After the Protocol, Documentation, Storage, and Reporting

Documentation standards

Every purity verification run should be recorded in a permanent laboratory notebook or electronic laboratory notebook (ELN) entry that includes: instrument identification and calibration status, operator name, date and time, sample identity and batch number, preparation details (mass weighed, diluent used, final concentration), system suitability results, raw chromatograms or spectra as exported files, integration parameters and peak table, calculated purity value with units and method, and any deviations from the standard protocol with scientific justification. 9

Raw data files (chromatograms, MS spectra) must be stored in their native instrument format, not only as exported PDFs or images, because native files allow retrospective re-integration if integration parameters are questioned. Many institutions now require ELN entries for all analytical data as part of GLP compliance or research integrity programs; even for non-GLP research, the same discipline dramatically improves reproducibility and troubleshooting capability when experiments are repeated months later.

Cross-reference your purity verification record with the supplier's CoA and with the how-to-read-coa guide checklist. When your independent data agrees with the CoA within experimental uncertainty (typically ±2% for area-percent), this builds justified confidence in the supplier. When it disagrees by more than 3%, the discrepancy should be reported to the supplier and the batch quarantined until resolved. Our supplier selection guide describes how responsiveness to analytical discrepancies should factor into vendor relationship decisions.

Storage of verified peptide stocks

Once purity has been confirmed, the storage conditions for the verified stock must preserve the measured purity until experimental use. General principles from the published literature on peptide stability include:

• Lyophilised powder is more stable than dissolved stock; return excess material to lyophilised form under vacuum if storage exceeds one week. 12
• Dissolved stocks for short-term use (≤72 hours): −20 °C in single-use aliquots in polypropylene tubes, headspace blanketed with nitrogen. 12
• Long-term dissolved stocks: −80 °C with desiccant in the cryovial, avoiding multiple freeze-thaw cycles that accelerate aggregation.
• Cysteine-containing peptides: do not freeze-thaw more than twice; each cycle increases disulfide impurity burden measurably.
• Avoid storing dissolved peptides in glass at pH >7; silanol groups leach from glass and catalyse certain degradation reactions. 7

Record the storage date, condition, and concentration of each aliquot. A verified stock degrades on a timeline that is peptide-specific; do not assume the purity data from Month 1 applies to a stock used in Month 6 without re-verification.

Reporting purity in publications and lab records

When reporting purity in a manuscript or internal report, use the following minimum disclosure format:

"Peptide [name/sequence] was analysed by RP-HPLC on a C18 column (4.6 × 150 mm, 5 µm, 300 Å) using a 5-65% acetonitrile gradient in 0.1% TFA over 30 minutes, UV detection at 214 nm, with area-percent purity determined from triplicate injection. Molecular weight was confirmed by ESI-MS (observed: X.XX Da; theoretical: X.XX Da). Purity was [X.X ± X.X]%."

This format, adapted from guidelines published in the Journal of Peptide Science author instructions, allows readers to assess the method and compare results across laboratories. 3

Worked Examples

Example 1: BPC-157 analogue (ten-residue, linear peptide, no Cys)

Scenario: A 10 mg vial of a synthetic BPC-157 research analogue (sequence GEPPPGKPDD, MW = 994.07 Da average; 993.04 Da monoisotopic) arrives with a CoA reporting 97.3% purity by RP-HPLC.

Step 1, Weighing: 1.52 mg weighed on calibrated analytical balance; recorded as 1.520 ± 0.005 mg.

Step 2, Stock preparation: Dissolved in 1.520 mL of 0.1% TFA/water to give a nominal concentration of 1.00 mg/mL (1.006 mM based on average MW).

Step 3, RP-HPLC results: Three injections yield main peak areas of 1,423,440; 1,421,870; 1,424,110 mAU·s. Mean = 1,423,140 mAU·s, RSD = 0.08% (system suitability passed). Two minor impurity peaks at 11.2 minutes (area 2.1%) and 14.8 minutes (area 0.9%). Calculated area-percent purity = 1,423,140 / (1,423,140 + 30,012 + 12,828) × 100 = 97.0%.

This is within 0.3% of the CoA value, supporting supplier accuracy. The impurity at 11.2 minutes (earlier-eluting, more hydrophilic) is consistent with a deletion or deamidation product; the 14.8-minute peak (later-eluting) may represent an oxidised or protected variant.

Step 4, ESI-MS: Direct infusion in 50% ACN / 0.1% formic acid yields multiply-charged ions: [M+H]⁺ = 994.1 Da, [M+2H]²⁺ = 497.6 Da. Deconvoluted MW = 993.1 Da. Theoretical monoisotopic MW = 993.04 Da. Δ = +0.06 Da. Confirmed identity. Impurity at 11.2 minutes (fraction collected): [M+H]⁺ = 965.1 Da (Δ = −29 Da vs main peptide; consistent with a two-residue deletion or truncation). Impurity at 14.8 minutes: [M+H]⁺ = 1009.1 Da (Δ = +16 Da; consistent with methionine oxidation, though this sequence contains no Met, the +16 offset may indicate tryptophan oxidation if a Trp-containing variant is present, or more likely a glycine-to-alanine substitution artefact).

Step 5, Conclusion: The independent purity verification confirms the CoA value within measurement uncertainty, identifies the two impurities structurally, and clears the batch for use in experiments where >95% purity is acceptable. Stoichiometric dosing experiments should be preceded by AAA to determine true content.

Example 2: Oxytocin (nine-residue cyclic disulfide peptide, MW 1,007.19 Da)

Scenario: A research oxytocin batch is received with a CoA showing 99.1% purity. The sequence is CYIQNCPLG-NH₂ with a Cys1-Cys6 disulfide bridge.

Step 1, Weighing and dissolution: 2.05 mg weighed. Dissolved in 1.00 mL of 0.1% TFA/water (2.05 mg/mL stock). One centrifugation pellet observed (small white residue, estimated mass <0.1 mg based on tube tare weight before and after pellet drying, approximately 4.5% of total mass insoluble).

Step 2, RP-HPLC: Area-percent purity of clarified supernatant = 98.7%. This is 0.4% lower than the CoA value, within experimental uncertainty, but the 4.5% insoluble fraction indicates that the true purity of the complete sample is approximately 98.7% × 95.5% = 94.3% of nominal mass in soluble, pure form. This distinction matters for dose calculation in animal studies.

Step 3, Ellman's assay: Ellman's reagent added to 2.0 nmol of peptide in phosphate buffer pH 8.0. Absorbance at 412 nm = 0.003 (near blank). Expected: 0 free thiols (both Cys residues should be disulfide-bonded in correctly folded oxytocin). Result consistent with complete disulfide formation, structurally correct.

To confirm both thiols are oxidised (rather than one being in a mixed disulfide with a contaminant), TCEP reduction followed by Ellman's assay: after TCEP (5 mM, 30 min), Abs₄₁₂ = 0.141. Using ε = 14,150 M⁻¹cm⁻¹ and 0.5 cm path length: free thiol concentration = 0.141 / (14,150 × 0.5) = 19.9 µM in a 2 nmol / 0.1 mL = 20 µM nominal solution. Yield: 19.9/20 = 99.5% of theoretical thiols recovered after TCEP. Confirms both Cys residues are in an intramolecular disulfide (not crosslinked aggregates or mixed disulfides with contaminants).

Step 4, ESI-MS: Deconvoluted MW = 1,007.2 Da (average). Theoretical = 1,007.19 Da (average). Δ = +0.01 Da. Confirmed. No +2 Da peak (which would indicate a reduced, non-cyclised form) detected above 0.5% relative abundance.

Step 5, Conclusion: Despite the CoA reporting 99.1%, the effective usable purity (soluble fraction) is approximately 94.3% of nominal mass. Researchers using this batch must account for ~5% insoluble material when calculating working concentrations, or filter and re-quantify by AAA. The disulfide structure is verified as correct.

Example 3: GLP-1(7-36)amide analogue (30-residue, linear, MW ~3,298 Da)

Scenario: A 30-residue GLP-1 research analogue is received. The CoA reports 95.8% purity. The research team needs to confirm this and determine the absolute concentration for receptor binding assays with Kd in the picomolar range, meaning stoichiometric accuracy within ±5% is required.

Step 1, RP-HPLC: Four major impurity peaks detected totalling 5.1% of total peak area, giving an independent area-percent purity of 94.9%. This is 0.9% below the CoA, within measurement uncertainty but at the lower boundary. The team decides to proceed to AAA for absolute quantitation.

Step 2, ESI-MS (LC-MS with ammonium formate mobile phase): The 30-residue peptide generates a complex charge-state envelope ([M+4H]⁴⁺ through [M+8H]⁸⁺). Deconvolution yields experimental MW = 3,297.8 Da; theoretical = 3,298.3 Da; Δ = −0.5 Da. Confirmed identity within instrument measurement uncertainty of ±1 Da for this mass range on a single-quadrupole instrument.

Step 3, AAA with quantitative calculation: The GLP-1 analogue contains one phenylalanine (Phe) residue at position 28. After acid hydrolysis (6 N HCl, 110 °C, 24 h), the hydrolysate is derivatised with AccQ·Tag and analysed by reversed-phase AAA. Peak area for Phe = 24,310 response units. From a five-point calibration curve with authentic Phe standard (1-50 nmol/mL), the Phe concentration in the hydrolysate = 4.22 nmol in 100 µL hydrolysate volume.

Calculation:

• Moles of peptide in hydrolysate = moles of Phe (one Phe per molecule) = 4.22 nmol
• Volume of original stock aliquot used for hydrolysis = 50 µL
• Therefore, concentration of peptide in stock = 4.22 nmol / 0.050 mL = 84.4 nmol/mL = 84.4 µM
• Nominal concentration based on weighing and average MW: 90.4 µM
• True content = 84.4 / 90.4 × 100 = 93.4% of nominal mass

This is meaningfully below the nominal concentration and below the purity assessed by RP-HPLC. The discrepancy (93.4% by AAA vs 94.9% by RP-HPLC area-percent) is consistent with a small amount of UV-transparent impurity (likely residual TFA salt or counter-ion) that contributes to mass but not to UV absorbance and not to amino acid composition.

Step 4, Practical implication: For a receptor binding assay targeting a Kd of 50 pM, all working dilutions must be recalculated using the AAA-determined concentration (84.4 µM stock) rather than the nominal concentration (90.4 µM). Using the nominal value would systematically underestimate receptor occupancy by approximately 7% at all concentrations, shifting the apparent Kd by the same proportion, a meaningful error in a precise binding study.

FAQ